Recombinant Human Neuropilin-1 Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Neuropilin-1 (Npn-1, also known as neuropilin and CD304) is a 130-140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis (1-4). The full-length 923 amino acid (aa) human Npn-1 isoform 1 contains an 835 aa extracellular domain (ECD) that shows 92-95% aa identity with mouse, rat, bovine and canine Npn-1 (3, 4). The ECD contains two N-terminal CUB domains (termed a1a2), two domains with homology to coagulation factors V and VIII (b1b2) and a MAM (meprin) domain (c). C-terminally divergent splice variants with 704, 644, 609, and 551 aa lack the MAM and TM domains and are demonstrated or presumed to be soluble antagonists (1, 5-7). A 906 aa form lacks a TM segment, but secretion has not been found (8). The sema domains of Class III secreted semaphorins such as Sema3A bind Npn-1 a1a2 (9). Heparin, the heparin-binding forms of VEGF (VEGF 165, VEGF-B and VEGF-E), PlGF (PlGF2), and the C-terminus of Sema3 bind the b1b2 region (9, 10). Npn-1 and Npn-2 share 48% aa identity within the ECD and can form homo- and hetero-oligomers via interaction of their MAM domains (1). Neuropilins show partially overlapping expression in neuronal and endothelial cells during development (1, 2). Both neuropilins act as co-receptors with plexins, mainly plexin A3 and A4, to bind class III semaphorins that mediate axon repulsion (11). However, only Npn-1 binds Sema3A, and only Npn-2 binds Sema3F (1). Both are co-receptors with VEGF R2 (also called KDR or Flk-1) for VEGF 165 binding (1). Sema3A signaling can be blocked by VEGF 165, which has higher affinity for Npn-1 (12). Npn-1 is preferentially expressed in arteries during development or those undergoing remodeling (1, 2). Npn-1 is also expressed on dendritic cells and mediates DC-induced T cell proliferation (13). Npn-1 is a marker of CD4+ Treg cells and a population of CD8+ T-cells infiltrating solid tumors. Immunotherapies that block Npn-1 synergizes with anti-PD-1 to enhance CD8+ proliferation and response (14). There is evidence that Npn-1 with VEGF-A plays a role in stemness of breast cancer cell by activating Wnt/b-catenin pathway (15).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: Bioassay.

Showing Publications 1 - 2 of 2.

Publications using 10455-N1	Applications	Species
N Gioelli, LJ Neilson, N Wei, G Villari, W Chen, B Kuhle, M Ehling, F Maione, S Willox, S Brundu, D Avanzato, G Koulouras, M Mazzone, E Giraudo, XL Yang, D Valdembri, S Zanivan, G Serini Neuropilin 1 and its inhibitory ligand mini-tryptophanyl-tRNA synthetase inversely regulate VE-cadherin turnover and vascular permeability Nature Communications, 2022-07-20;13(1):4188. 2022-07-20 [PMID: 35858913] (Bioassay, Human)	Bioassay	Human
J Huang, S Zhang Overexpressed Neuropilin-1 in Endothelial Cells Promotes Endothelial Permeability through Interaction with ANGPTL4 and VEGF in Kawasaki Disease Mediators of Inflammation, 2021-08-13;2021(0):9914071. 2021-08-13 [PMID: 34434074] (Bioassay, Human)	Bioassay	Human

Array 10455-N1

• Neuropilin-1 Antibodies
• Neuropilin-1 Lysates
• Neuropilin-1 Protein
• Neuropilin-1 Proteins and Enzymes
• Neuropilin-1 ELISAs